cagrilintide + semaglutide
The Book of Peptides is not a clinic and not your doctor. We do not sell, prescribe, recommend, or personalize any compound, and no grade or ranking here is an endorsement. In the United States, most of these compounds are not FDA-approved and are sold for laboratory research only; a few are prescription drugs, and some are controlled substances or banned in sport. Possessing or administering an unapproved compound outside an authorized setting may be unlawful. Nothing here is a recommendation to buy, possess, or self-administer anything. Consult a licensed physician before any decision involving peptide use.
Not reconstituted — vialsdelivery, so there's no vial to draw from.
CagriSema is a fixed-dose combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide, showing ~22.7% mean weight loss at 68 weeks in the REDEFINE 1 trial. Both components are individually well-characterized, but the combination itself is still investigational and not separately approved. It is heavily searched and sold as either a co-formulated product or paired vials.
